Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 58Head & Neck 9Gastrointestinal 9Tumor-Agnostic 6Gynecologic 6Other solid neoplasm 4Endocrine 3Thoracic 2Sarcoma 2Genitourinary 2Dermatologic 2Plasma cell 1CNS 1

Conditions

Multiple Endocrine Neoplasia Type 1 3Breast Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Hyperglycemia 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Alpelisib × Endocrine × Clear all
NCT05631795 2026-04-07

ALPINIST

Novartis

Phase 4 Completed
40 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1

NCT04300790 2025-07-29

METALLICA

MedSIR

Phase 2 Completed
69 enrolled
BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT02437318 2025-02-13

SOLAR-1

Novartis

Phase 3 Completed
572 enrolled 22 charts 1 FDA
BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡